{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:35:05Z","timestamp":1783488905210,"version":"3.55.0"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Livedoid vasculopathy is a rare, chronic, and recurrent disease with limited effective treatments. Its etiopathogenesis remains incompletely understood. Baricitinib, a selective Janus kinase 1 and 2 inhibitor, has been used to treat rheumatoid arthritis and could reduce the disease severity in patients with livedoid vasculopathy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively observed eight patients who received 2 mg\/day of baricitinib for the treatment of refractory livedoid vasculopathy. We evaluated their clinical scores before and after treatment to determine its effectiveness and safety.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Improvement in livedoid vasculopathy was observed with significant regression in the clinical scores after baricitinib treatment. The mean clinical scores were 7.0 \u00b1 1.6 and 1.4 \u00b1 1.2 before and after baricitinib treatment, respectively (P &amp;lt;0.01). Furthermore, six out of the eight patients achieved a clinical score of 0 or 2 after treatment. These scores indicated remission. Clinical findings, including erythema, ulceration, and pain, improved in all the patients. The remission times ranged from 3 to 13 weeks, with a mean remission time of 7.75 \u00b1 3.45 weeks. There were no reports of adverse events in any patient.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our study showed that baricitinib treatment was safe and could significantly relieve the signs and symptoms of livedoid vasculopathy. However, randomized controlled studies should be conducted to confirm these results.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.1008392","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T04:38:30Z","timestamp":1666845510000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["Baricitinib is potentially effective in the treatment of refractory livedoid vasculopathy"],"prefix":"10.3389","volume":"13","author":[{"given":"Yuyang","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2965","article-title":"Livedoid vasculopathy: A French observational study including therapeutic options","volume":"98","author":"Gardette","year":"2018","journal-title":"Acta Derm Venereol."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.06.030","article-title":"Quality-of-life impairment in patients with livedoid vasculopathy","volume":"71","author":"Polo Gasc\u00f3n","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.4.447","article-title":"Livedo vasculopathy vs small vessel cutaneous vasculitis: cytokine and platelet p-selectin studies","volume":"134","author":"Papi","year":"1998","journal-title":"Arch Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.jaad.2013.07.019","article-title":"Livedoid vasculopathy: an in-depth analysis using a modified Delphi approach","volume":"69","author":"Alavi","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1001\/jamadermatol.2017.4374","article-title":"Treatment for livedoid vasculopathy: a systematic review","volume":"154","author":"Micieli","year":"2018","journal-title":"JAMA Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.183635","article-title":"Livedoid vasculopathy: a review of pathogenesis and principles of management","volume":"82","author":"Vasudevan","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16129","article-title":"Livedoid vasculopathy in koreans: clinical features and response to rivaroxaban treatment","volume":"34","author":"Lee","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.3260","article-title":"Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial","volume":"156","author":"Reich","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.0241","article-title":"Treatment of livedoid vasculopathy with baricitinib","volume":"158","author":"Song","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15659","article-title":"Refractory livedoid vasculopathy in a child successfully treated with baricitinib","volume":"35","author":"Zhang","year":"2022","journal-title":"Dermatol Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14470","article-title":"Refractory ulcerations associated with livedoid vasculopathy successfully treated with tofacitinib","volume":"33","author":"Jia","year":"2020","journal-title":"Dermatol Ther"},{"key":"B12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3899\/jrheum.161161","article-title":"Safety and efficacy of baricitinib through 128 weeks in an open-label, longterm extension study in patients with rheumatoid arthritis","volume":"45","author":"Keystone","year":"2018","journal-title":"J Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1008392\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T04:38:32Z","timestamp":1666845512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1008392\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,27]]},"references-count":12,"alternative-id":["10.3389\/fimmu.2022.1008392"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1008392","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,27]]},"article-number":"1008392"}}